Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Neoplasia (New York, N.Y.)
|
November 4, 2024
Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center
Jens von der Grün, Maiwand Ahmadsei, Isabel Breyer, et al.
EMBO Molecular Medicine
|
February 13, 2023
Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma
Lara Planas-Paz, Alicia Pliego-Mendieta, Catherine Hagedorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2018
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients
Paulino Tallón de Lara, Virginia Cecconi, Stefanie Hiltbrunner, et al.
Clinical Lung Cancer
|
April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Remi Veillon, Hiroshi Sakai, Xiuning Le, et al.
JTO Clinical and Research Reports
|
December 3, 2024
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
Sabine Schmid, Lisa Holer, Katrin Gysel, et al.
Cancers
|
May 14, 2022
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
Markus Joerger, Yannis Metaxas, Khalil Zaman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2024
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Ross A Soo, Urania Dafni, Ji-Youn Han, et al.
JAMA Oncology
|
November 8, 2019
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Kimberley M Heinhuis, Matteo Carlino, Markus Joerger, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial
Enriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Nature Communications
|
August 21, 2025
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target
Willemijn Breunis, Eva Brack, Anna C Ehlers, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Neoplasia (New York, N.Y.)
|
November 4, 2024
Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center
Jens von der Grün, Maiwand Ahmadsei, Isabel Breyer, et al.
EMBO Molecular Medicine
|
February 13, 2023
Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma
Lara Planas-Paz, Alicia Pliego-Mendieta, Catherine Hagedorn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2018
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients
Paulino Tallón de Lara, Virginia Cecconi, Stefanie Hiltbrunner, et al.
Clinical Lung Cancer
|
April 25, 2022
Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
Remi Veillon, Hiroshi Sakai, Xiuning Le, et al.
JTO Clinical and Research Reports
|
December 3, 2024
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
Sabine Schmid, Lisa Holer, Katrin Gysel, et al.
Cancers
|
May 14, 2022
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)
Markus Joerger, Yannis Metaxas, Khalil Zaman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 9, 2024
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Ross A Soo, Urania Dafni, Ji-Youn Han, et al.
JAMA Oncology
|
November 8, 2019
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
Kimberley M Heinhuis, Matteo Carlino, Markus Joerger, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 28, 2022
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial
Enriqueta Felip, Egbert F Smit, Miguel A Molina-Vila, et al.
Nature Communications
|
August 21, 2025
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target
Willemijn Breunis, Eva Brack, Anna C Ehlers, et al.
Page
of 5